On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk, a Trop-2-directed antibody and topoisomerase inhibitor...

MONDAY, Feb. 3, 2025 -- The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with...

Datopotamab deruxtecan (Dato─DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or...

27 January 2025 -- AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult...

On January 16, 2025, the Food and Drug Administration approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic...

The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United States.

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive...

Food and Drug Administration (FDA) approved a new medication called Journavx (suzetrigine) to treat moderate to severe acute pain in adults. This...

Updated Date: Thu, 30 Jan 2025 00:00:00 EST